The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•24 March 2026•

1 min read

Hoth Therapeutics Reports Positive Clinical Data for HT-001 Cancer Treatment

Key Facts

1Topical HT-001 showed a ~77% increase in drug exposure with minimal systemic absorption.

2Systemic absorption levels were ~99% lower compared to FDA-approved oral formulations.

3No serious adverse events or dose-limiting toxicities were observed during the study.

Hoth Therapeutics (HOTH) announced positive results from its clinical study of HT-001, a topical treatment for skin toxicities in cancer patients undergoing EGFR therapy. The data revealed a significant 77% increase in drug exposure while maintaining minimal systemic absorption. Crucially, systemic levels were approximately 99% lower than those found in FDA-approved oral formulations, significantly reducing potential side effects. No serious adverse events or dose-limiting toxicities were reported during the study, confirming a strong safety profile for the candidate. This milestone validates the company's approach to providing effective local treatment without the risks associated with systemic therapies. Investors view these results as a positive step forward for the company's oncology pipeline and its long-term growth potential.

Create Free Account